These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27022244)

  • 1. Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis.
    Krasselt M; Baerwald C
    Drug Des Devel Ther; 2016; 10():1047-58. PubMed ID: 27022244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis.
    Ursini F; Naty S; Bruno C; Grembiale RD
    Rev Recent Clin Trials; 2017; 12(2):124-128. PubMed ID: 28356031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis.
    Alten R
    Expert Rev Clin Immunol; 2012 Feb; 8(2):123-33. PubMed ID: 22288450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prednisone chronotherapy.
    Spies CM; Cutolo M; Straub RH; Burmester GR; Buttgereit F
    Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S42-5. PubMed ID: 22018182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone.
    Alten R; Döring G; Cutolo M; Gromnica-Ihle E; Witte S; Straub R; Buttgereit F
    J Rheumatol; 2010 Oct; 37(10):2025-31. PubMed ID: 20682671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified-release prednisone: in patients with rheumatoid arthritis.
    Henness S; Yang LP
    Drugs; 2013 Dec; 73(18):2067-76. PubMed ID: 24249648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis.
    Buttgereit F; Doering G; Schaeffler A; Witte S; Sierakowski S; Gromnica-Ihle E; Jeka S; Krueger K; Szechinski J; Alten R
    Ann Rheum Dis; 2010 Jul; 69(7):1275-80. PubMed ID: 20542963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).
    Buttgereit F; Mehta D; Kirwan J; Szechinski J; Boers M; Alten RE; Supronik J; Szombati I; Romer U; Witte S; Saag KG
    Ann Rheum Dis; 2013 Feb; 72(2):204-10. PubMed ID: 22562974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.
    Buttgereit F; Doering G; Schaeffler A; Witte S; Sierakowski S; Gromnica-Ihle E; Jeka S; Krueger K; Szechinski J; Alten R
    Lancet; 2008 Jan; 371(9608):205-14. PubMed ID: 18207016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone.
    Alten R; Holt R; Grahn A; Rice P; Kent J; Buttgereit F; Gibofsky A
    Scand J Rheumatol; 2015; 44(5):354-8. PubMed ID: 26114379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.
    Buttgereit F; Kent JD; Holt RJ; Grahn AY; Rice P; Alten R; Yazici Y
    Bull Hosp Jt Dis (2013); 2015 Jul; 73(3):168-77. PubMed ID: 26535595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability.
    Bandinelli F; Scazzariello F; Pimenta da Fonseca E; Barreto Santiago M; Marcassa C; Nacci F; Matucci Cerinic M
    Drug Des Devel Ther; 2016; 10():3717-3724. PubMed ID: 27881910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified release prednisone in patients with rheumatoid arthritis.
    Jacobs JW; Bijlsma JW
    Ann Rheum Dis; 2010 Jul; 69(7):1257-9. PubMed ID: 20525834
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids.
    Cutolo M; Iaccarino L; Doria A; Govoni M; Sulli A; Marcassa C
    Clin Exp Rheumatol; 2013; 31(4):498-505. PubMed ID: 23415134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed-release prednisone - a new approach to an old therapy.
    Buttgereit F; Gibofsky A
    Expert Opin Pharmacother; 2013 Jun; 14(8):1097-106. PubMed ID: 23594208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective initial and long-term prednisone in doses of less than 5 mg/day to treat rheumatoid arthritis--documentation using a patient self-report Multidimensional Health Assessment Questionnaire (MDHAQ).
    Pincus T; Castrejón I
    Bull NYU Hosp Jt Dis; 2012; 70 Suppl 1():14-20. PubMed ID: 23259653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current relevance and use of prednisone in rheumatoid arthritis.
    Krasselt M; Baerwald C
    Expert Rev Clin Immunol; 2014 May; 10(5):557-71. PubMed ID: 24717015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of glucocorticoids in rheumatoid arthritis.
    Spies CM; Bijlsma JW; Burmester GR; Buttgereit F
    Curr Opin Pharmacol; 2010 Jun; 10(3):302-7. PubMed ID: 20202903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone.
    Eberhardt R; Krüger K; Reiter W; Gross W; Zwingers T
    Arzneimittelforschung; 1994 May; 44(5):642-7. PubMed ID: 8024639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis.
    Derendorf H; Ruebsamen K; Clarke L; Schaeffler A; Kirwan JR
    J Clin Pharmacol; 2013 Mar; 53(3):326-33. PubMed ID: 23444285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.